Compare Novartis with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SANOFI INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SANOFI INDIA NOVARTIS/
SANOFI INDIA
 
P/E (TTM) x 494.1 34.8 1,419.3% View Chart
P/BV x 28.7 6.1 470.0% View Chart
Dividend Yield % 1.6 1.4 111.6%  

Financials

 NOVARTIS   SANOFI INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
SANOFI INDIA
Dec-18
NOVARTIS/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7586,840 11.1%   
Low Rs5794,630 12.5%   
Sales per share (Unadj.) Rs228.41,203.1 19.0%  
Earnings per share (Unadj.) Rs31.7165.3 19.2%  
Cash flow per share (Unadj.) Rs32.8209.9 15.6%  
Dividends per share (Unadj.) Rs10.0084.00 11.9%  
Dividend yield (eoy) %1.51.5 102.1%  
Book value per share (Unadj.) Rs297.1963.6 30.8%  
Shares outstanding (eoy) m24.6923.03 107.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.94.8 61.4%   
Avg P/E ratio x21.134.7 60.7%  
P/CF ratio (eoy) x20.427.3 74.7%  
Price / Book Value ratio x2.26.0 37.8%  
Dividend payout %31.550.8 62.0%   
Avg Mkt Cap Rs m16,505132,078 12.5%   
No. of employees `0000.73.3 20.2%   
Total wages/salary Rs m1,4454,068 35.5%   
Avg. sales/employee Rs Th8,441.38,393.8 100.6%   
Avg. wages/employee Rs Th2,163.61,232.4 175.6%   
Avg. net profit/employee Rs Th1,173.11,153.0 101.7%   
INCOME DATA
Net Sales Rs m5,63927,708 20.4%  
Other income Rs m1,718897 191.6%   
Total revenues Rs m7,35728,605 25.7%   
Gross profit Rs m-636,235 -1.0%  
Depreciation Rs m251,027 2.5%   
Interest Rs m557 790.0%   
Profit before tax Rs m1,5756,098 25.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7922,292 34.5%   
Profit after tax Rs m7843,806 20.6%  
Gross profit margin %-1.122.5 -4.9%  
Effective tax rate %50.337.6 133.7%   
Net profit margin %13.913.7 101.2%  
BALANCE SHEET DATA
Current assets Rs m9,52215,922 59.8%   
Current liabilities Rs m3,2966,235 52.9%   
Net working cap to sales %110.435.0 315.8%  
Current ratio x2.92.6 113.1%  
Inventory Days Days3764 57.5%  
Debtors Days Days2821 136.2%  
Net fixed assets Rs m467,539 0.6%   
Share capital Rs m123230 53.7%   
"Free" reserves Rs m7,21321,962 32.8%   
Net worth Rs m7,33622,192 33.1%   
Long term debt Rs m00-   
Total assets Rs m11,10529,839 37.2%  
Interest coverage x29.5872.1 3.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.9 54.7%   
Return on assets %7.612.8 59.1%  
Return on equity %10.717.2 62.3%  
Return on capital %22.227.5 80.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m617,587 0.8%   
Fx outflow Rs m3,6307,145 50.8%   
Net fx Rs m-3,570442 -807.6%   
CASH FLOW
From Operations Rs m1,6103,739 43.1%  
From Investments Rs m687-731 -94.0%  
From Financial Activity Rs m-2,677-1,972 135.7%  
Net Cashflow Rs m-3801,036 -36.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 2.0 14.4 13.9%  
FIIs % 1.6 14.6 11.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 15,184 274.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  PFIZER  DR. DATSONS LABS  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 16, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS